PD Dr. med. Vikas Prasad

Leitender Oberarzt

Klinik für Nuklearmedizin, Universität Ulm
Albert-Einstein-Allee 23, 89081 Ulm, Deutschland

Telefon: 0731 500-61310
Fax: 0731 500-61302

E-Mail: vikas.prasad@uniklinik-ulm.de
            vikas.prasad@charite.de

Deputy Director

Department of Nuclear Medicine, University of Ulm
Albert-Einstein-Allee 23, 89081 Ulm, Germany

Telephone: 0731 500-61310
Fax: 0731 500-61302

E-Mail: vikas.prasad@uniklinik-ulm.de
            vikas.prasad@charite.de

 

10/2007

Fellowship of European Board of Nuclear Medicine Examination

11/2009

Facharzt (Nuclear Medicine Specialization), LÄK Thüringen (Jena), Germany

03/2010

Fachkunde in Nuclear Medicine (Radiation Safety Officer), Germany

08/2011

Gleichwertigkeitsprüfung (Approbation), LÄK, Berlin

14.10.2016

Dr.med Thesis titled ‘Somatostatin receptor PET/CT in the management of patients with neuroendocrine tumors’

13.02.2017

Habilitation

01/2006-10/2007

Clinical Research Associate in the Department of Nuclear Medicine and Centre for PET/CT at Zentralklinik Bad Berka GmbH, Germany

11/2007-11/2009

Residency in Nuclear Medicine at the Department of Nuclear Medicine and Centre for PET/CT at Zentralklinik Bad Berka GmbH, Germany

12/2009-01/2011

Senior Physician, Nuclear Medicine, Department of Nuclear Medicine and Centre for PET/CT at Zentralklinik Bad Berka GmbH, Germany

02/2011-15.01.2018

Senior Physician, Department of Nuclear Medicine, Charité Universitätsmedizin Berlin, Germany

12/2012-15.01.2018

Lehrbeauftragter (Teacher In-Charge, Undergraduate Medical Education Programme) of the Department of Nuclear Medicine, Charité Universitätsmedizin Berlin, Germany

10/2017-15.01.2018

Member, Promotionkommission Charité Universitätsmedizin Berlin, Germany

Since 16.01.2018

Ltd. Oberarzt (Deputy Director), Department of Nuclear Medicine, Uniklinik Ulm, Ulm, Germany

  1. PET/CT in Oncology- Neuroendocrine tumor, prostate cancer, lung cancer, lymphoma and sarcoma, correlation of PET with biomarkers and immunohistochemistry
  2. Radionuclide therapy in oncology- Peptide Receptor Radionuclide Therapy of neuroendocrine tumor and prostate cancer (Lu-177 DOTATATE, Lu-177 DOTATOC, Lu-177 PSMA), I-131 MIBG, Radium 223 therapy and Zevalin
  3. Preclinical applications of molecular imaging using micro PET/CT
  4. Development of new radiopharmaceuticals
  5. Digital Pathology
  6. Development of new hardware and software for molecular imaging using radiolabelled substances
  7. Nuclear Cardiology
  1. Grants (approximately 500.000 Euro), including FP7 EU Project: BetaCure Project (as Project Coordinator Nuclear Medicine)
  2. Deutsche Forschungsgemeinschaft (DFG) grants (co-applicant)

                    a.  C-11 synthesis module (co-applicant)
                    b.  PET/MRI scanner (co-applicant)

  3. German Cancer Consortium (DKTK)
                    a.  Overall 7 projects in clinical (3) and preclinical phase (4) out of which 3 have received grant and the rest are currently being evaluated. The projects are related to Ga-68 PSMA PET/CT, Lu-177 PSMA radionuclide therapy and radionuclide imaging and therapy of neuroendocrine tumors.
  • Radionuclide Therapy Committee of German Nuclear Medicine Society (DGN Therapie AG)
  • German Nuclear Medicine Society (DGN) Young Professional Committee
  • Have served on the Radiopharmaceutical Committee of the Society of Nuclear Medicine, US
  • PRRT Advisory Board – Novartis and Ipsen
  • Neuroblastoma Study Group, GPOH

 

International Research Collaborations

  • Post Graduate Institute of Medical Education and research, Chandigarh, India
  • Yale University School of Medicine and WREN Laboratory (Prof. IM Modlin), New Haven US
  • University of Cape Town, South Africa
  • Principle Investigator (multicenter, International): Peptide Receptor Radionuclide Therapy (PRRT) in Combination with Lanreotide Autogel: A Retrospective Study in Progressive Digestive and Bronchopulmonary Neuroendocrine Tumors (PRELUDE)
  • Co-Investigator in IAEA Research Contract No. 15505 on Establish Key Co-ordinates and Quality Systems for the evaluation of clinical efficacy of 68Ga- NOTA-c(RGDyk) for angiogenesis component in lung cancer (Phase II Clinical Trial)
  • Co-investigator in the BEST-NET therapy option- NIH registered
  • Co-investigator in PANTHERA Study
  • Co-investigator- A phase Ib study of fractionated Y-90 hPAM4 plus gemcitabine in patients with previously untreated advanced pancreatic cancer
  • Co Investigator in the SORAMEC Study
  • Co Investigator PETAL Study
  • Co Investigator PET-Plan Study
  • Co Investigator C25002 Brentuximab-Vedotin Study-Lymphoma
  • Co Investigator ‘Optimal’ Study -Lymphoma
  • Co Investigator NETTER-1 Phase III Study-Neuroendocrine Tumor
  • Co investigator ESCALOX Study-PET/CT in Radiation Therapy Planning of Head and Neck Tumor
  • Co investigator BetaCure FP7 EU Project
  • Co investigator COMPETE study
  • Co investigator in DKFZ/ DKTK Ga-68 PSMA PET/CT in prostate cancer
  • Supervising Dr.med Thesis on the role of dynamic FET PET and MRI in the better prediction of viable tumor in patients after cyber knife treatment
  • Co-investigator of a prospective, multicentre trial on the value of 18F- FET PET in the post-therapeutic evaluation of childhood brain tumours (FET PET 2010; EudraCT-Nummer: 2008-005786-60)
  • Journal of Nuclear Medicine
  • Annals of Nuclear Medicine
  • European Journal of Nuclear Medicine And Molecular Imaging
  • European Journal of Nuclear Medicine And Molecular Imaging Research
  • RöFö
  • Nuklearmedizin
  • Journal Of Gastreoneterology and Hepatology
  • Neuroendocrinology
  • Nuclear Medicine Communication
  • Clinical Nuclear Medicine
  • Molecular Imaging and Biology
  • Theranostics
  • Oncotarget
  • JCEM
  • Radiation Oncology

Member Of Editorial Board

Journal of Post Graduate Medicine Education and Research

Editor

Guest editing of monographic issue of QJNM on the use of mAb in inflammation and infection imaging. Quarterly Journal of Nuclear Medicine and Molecular Imaging

  • Teaching the medical students at Charité Universitätsmedizin Berlin since 06/2011
  • Teaching experience of two and half years at Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
  • Teaching experience in several CMEs organized across the world
  1. Best paper award, “Carcinoma Tongue: Time to review management protocol”, Singh Harsimran, Prasad Vikas, Singh Baljinder, Bhattacharya A, Mittal BR and Gupta Ashok; held at 39. North West Zone Meeting,  India of ENT Forum, October 1-2, 2005:
  2. Award for the best scientific presentation 18th IRIST Meeting 2006, London, UK
  3. Best poster presentation award WCNMB 2006: Ga-68 DOTA-NOC for determining the somatostatin receptor (sstr) status of neuroendocrine tumors (NET) before and after peptide receptor radionuclide therapy (PRRT): Clinical Experience after 1,027 receptor PET/CT studies. Richard P Baum, Vikas Prasad, Jochen Leonhardi, Renate Kroeger, Ruediger Wortmann, Dirk Mueller, Frank Roesch.
  4. Fellow European Board of Nuclear Medicine (FEBNM) 2007
  5. Fellow DKTK School of Oncology, 2014
  6. 3rd Prize (co-author) in the clinical section at 8th ENETS 2011 meeting at the Lissabon, Porugal, on the genetic mapping for detection of unknown primary
  7. 3rd Prize in the Clinical Section at ENETS Annual Meeting, 2009: Role of somatostatin receptor scintigraphy and peptide receptor radionuclide therapy in the
  8. Honorary Fellow of Indian College of Nuclear Medicine, Dec. 2017
  • Pulse Polio 1999, Indore , India
  • Indo-German Symposium, 2005 New Delhi
  • 10th Anniversary of The Department of Nuclear Medicine, Zentralklinik Bad Berka, 2008 Germany
  • Patient’s Day- Neuroendocrine Tumor 2011,  2012, 2013, 2014 Berlin
  • Masterclass in NET 2011 (Dublin), Berlin (2012), 2014 (Belgium) 2015 (London)
  • Second World Congress on Gallium 68 (2013), PGIMER Chandigarh, India
  • Indo-German CME 2013, PGIMER Chandigarh India
  • CME session – German Nuclear Medicine Society Annual Meeting 2014
  • DGN Summer School 2014-2017
  • ENETS 2018, Barcelona: Interactive Workshop – Gastroenterologist and Nuclear Medicine View
  • DGN 2018, Bremen: Precongress Symposium on ‘Theranostic’
  1. Editorial Board, Journal of Post Graduate Medical Education and Research
  2. Executive Member, Radiopharmaceutical Science Committee, Society of Nuclear Medicine (SNM), US
  3. Society of Nuclear Medicine (SNM), US
  4. Executive Member, SNM, Young Professional Committee
  5. European Association of Nuclear Medicine (EANM)
  6. European Neuroendocrine Tumor Society (ENETS)
  7. German Nuclear Medicine Society (DGN)
  8. North American Neuroendocrine Tumor Society (NANETS)
  9. Society of Nuclear Medicine and Molecular Imaging, India
  10. Indian Medical Council, India
  11. MP Medical Council, India
  • Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostatin analogue  DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging. 2010 Feb;54(1):61-7
  • Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010 Jan; 37(1):67-77
  • Kaemmerer D, Prasad V, Daffner W, Haugvik SP, Senftleben S, Baum RP, Hommann M. Radioguided surgery in neuroendocrine tumors using Ga-68-labeled somatostatin analogs: a pilot study. Clin Nucl Med. 2012 Feb;37(2):142-7 (splitted first author)
  • Sainz-Esteban A, Prasad V, Schuchardt C, Zachert C, Carril JM, Baum RP. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):501-11 (splitted first author)
  • Pumberger M, Prasad V, Druschel C, Disch AC, Brenner W, Schaser KD. Quantitative in vivo fusion assessment by (18)F-fluoride PET/CT following en bloc spondylectomy. Eur Spine J. 2015 Sep 15. [Epub ahead of print] PubMed PMID: 26374129 (splitted first author)
  • Prasad V, Steffen IG, Pavel M, Denecke T, Tischer E, Apostolopoulou K, Pascher A, Arsenic R, Brenner W. Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids. EJNMMI Res. 2015 Dec;5(1):53
  • Prasad V, Steffen I.G., Diederichs G, Makowski M.R., Wust P, Brenner W.  Biodistribution of 68Ga- PSMA-11 in patients with prostate cancer: characterization of uptake in normal organs and tumor lesions. Mol Imaging Biol. 2016 Jun;18(3):428-36
  • Prasad V, Sainz-Esteban A, Arsenic R, Plöckinger U, Denecke T, Pape Ulrich-Frank, Pascher A, Kühnen P, Pavel M, Blankenstein O.  Sensitivity and specificity of 68Ga somatostatin receptor PET/CT for endogeneous hyperinsulinemic focus- an explorative study. Eur J Nucl Med Mol Imaging. 2016 Aug;43(9)
  • Feyen O, Coy JF, Prasad V, Schierl R, Saenger J, Baum RP. EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol. 2012 Oct;8(10):1349-59 (splitted first author)
  • Prasad V, Tiling N, Denecke T, Brenner W, Plöckinger U. Potential Role of  Ga-68 DOTATOC PET/CT in von Hippel-Lindau Syndrome disease patients. Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):2014-20.
  • Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen JC, Huang K, Makowski MR, Brenner W, Prasad V. Immunohistochemical validation of PSMA-expression measured by 68Ga-PSMA PET/CT in primary prostate cancer. Nucl Med. 2017 Aug 3. pii: jnumed.117.195172. doi: 10.2967/jnumed.117.195172.
  • Dilz LM, Denecke T, Steffen IG, Prasad V, von Weikersthal LF, Pape UF, Wiedenmann B, Pavel M. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer. 2015 Jul;51(10):1253-62
  • Kaemmerer D, Wirtz RM, Fischer EK, Hommann M, Sänger J, Prasad V, Specht E, Baum RP, Schulz S, Lupp A. Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT data in patients with pancreatic neuroendocrine neoplasm. Pancreas. 2015 May;44(4):648-54
  • Badakhshi H, Graf R, Prasad V, Budach V. The impact of 18 F-FET PET-CT on target definition in image-guided stereotactic radiotherapy in patients with skull base lesions. Cancer Imaging. 2014 Jun 25;14:25
  • Geisel D, Lüdemann L, Fröling V, Malinowski M, Stockmann M, Baron A, Gebauer B, Seehofer D, Prasad V, Denecke T. Imaging-based evaluation of liver function: comparison of ⁹⁹mTc-mebrofenin hepatobiliary scintigraphy and Gd-EOB-DTPA-enhanced MRI. Eur Radiol. 2015 May;25(5):1384-91
  • Kaul D, Badakhshi H, Gevaert T, Pasemann D, Budach V, Tuleasca C, Gruen A, Prasad V, Levivier M, Kufeld M. Dosimetric comparison of different treatment modalities for stereotactic radiosurgery of meningioma. Acta Neurochir (Wien). 2015 Apr;157(4):559-63
  • Daniel K, Maria A, Amelie L, Isabell L, Stefan S, Luisa P, Merten H, Prasad V, Gerd B, Paul BR. Somatostatin receptor immunohistochemistry in neuroendocrine tumors: comparison between manual and automated evaluation. Int J Clin Exp Pathol. 2014 Jul 15;7(8):4971-80
  • Geisel D, Lüdemann L, Gebauer B, Fröling V, Prasad V, Heimann U, Stockmann M, Malinowski M, Hamm B, Brenner W, Denecke T. Optimized separation of left and right liver lobe in dynamic (99m)Tc-mebrofenin hepatobiliary scintigraphy using a hybrid SPECT-CT scanner. Ann Nucl Med. 2014 Nov;28(9):897-902
  • Kulkarni HR, Prasad V, Schuchardt C, Baum RP. Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose? Recent Results Cancer Res. 2013;194:561-6
  • Schuchardt C, Kulkarni HR, Prasad V, Zachert C, Müller D, Baum RP. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC. Recent Results Cancer Res. 2013;194:519-36
  • Kulkarni HR, Prasad V, Kaemmerer D, Hommann M, Baum RP. High uptake of (68)Ga-DOTATOC in spleen as compared to splenosis: measurement by PET/CT. Recent  Results Cancer Res. 2013;194:373-8. doi: 10.1007/978-3-642-27994-2-19
  • Kaemmerer D, Peter L, Lupp A, Schulz S, Sänger J, Baum RP, Prasad V, Hommann  M. Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol. 2012;5(3):187-94
  • Oh S, Prasad V, Lee DS, Baum RP. Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine  Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT. Int J Mol Imaging. 2011;:524130
  • Schreiter NF, Brenner W, Nogami M, Buchert R, Huppertz A, Pape UF, Prasad V, Hamm B, Maurer MH. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):72-82
  • Kaemmerer D, Peter L, Lupp A, Schulz S, Sänger J, Prasad V, Kulkarni H, Haugvik SP, Hommann M, Baum RP. Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1659-68
  • Shields CJ, Tiret E, Winter DC; International Rectal Carcinoid Study Group. Carcinoid tumors of the rectum: a multi-institutional international collaboration. Ann Surg. 2010 Nov;252(5):750-5
  • Baum RP, Prasad V, Müller D, Schuchardt C, Orlova A, Wennborg A, Tolmachev V, Feldwisch J. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med. 2010 Jun;51(6):892-7
  • Singh B, Sunil HV, Sharma S, Prasad V, Kashyap R, Bhattacharya A, Mittal BR,  Taneja A, Rai R, Goni VG, Aggarwal S, Gill SS, Bhatnagar A, Singh AK. Efficacy of indigenously developed single vial kit preparation of 99mTc-ciprofloxacin in the detection of bacterial infection: an Indian experience. Nucl Med Commun. 2008 Dec;29(12):1123-9 (part of DNB thesis in India)
  • Tuli HS, Singh B, Prasad V, Das A, Gupta AK, Mittal BR. Diagnostic accuracy of 99mTc-MIBI-SPECT in the detection of lymph node metastases in patients with carcinoma of the tongue: comparison with computed tomography and MRI. Nucl Med Commun. 2008 Sep;29(9):803-8
  • Singh B, Manoj R, Prasad V, Bhattacharya A, Sharma Y, Mittal BR. Comparison of left ventricular functional parameters measured by gated single photon emission tomography and by two-dimensional echocardiography. Hell J Nucl Med. 2006 May-Aug;9(2):94-8
  • Rai Mittal B, Singh S, Bhattacharya A, Prasad V, Singh B. Lung scintigraphy in the diagnosis and follow-up of pulmonary thromboembolism in children with nephrotic syndrome. Clin Imaging. 2005 Sep-Oct;29(5):313-6
  • Bodei L, Kidd M, Modlin IM, Prasad V, Severi S, Ambrosini V, Kwekkeboom DJ, Krenning EP, Baum RP, Paganelli G, Drozdov I. Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status. Eur J Nucl Med Mol Imaging.  2015 Aug;42(9):1341-52
  • Knie B, Plotkin M, Zschieschang P, Prasad V, Moskopp D.  A family with pheochromocytoma-paraganglioma inherited tumour syndrome. Serial 18F-DOPA PET/CT investigations. Nuklearmedizin. 2016 Jan 7;55(1)
  • Apostolova I, Hofheinz F, Buchert R, Steffen IG, Michel R, Rosner C, Prasad V, Köhler C, Derlin T, Brenner W, Marnitz S. Combined measurement of tumor perfusion and glucose metabolism for improved tumor characterization in advanced cervical carcinoma. A PET/CT pilot study using [15O]water and [18F]fluorodeoxyglucose. Strahlenther Onkol. 2014 Jun;190(6):575-81
  • Kaemmerer D, Posorski N, von Eggeling F, Ernst G, Hörsch D, Baum RP, Prasad V, Langer R, Esposito I, Klöppel G, Sehner S, Knösel T, Hommann M. The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasm. Clin Exp Metastasis. 2014 Oct; 31(7):817-27. Doi: 10.1007/s10585-014-9672-3.
  • Pavel M, Jann H, Prasad V, Drozdov I, Modlin IM, Kidd M. NET Blood Transcript Analysis defines the Crossing of the Clinical Rubicon: When Stable Disease becomes Progressive. Neuroendocrinology. 2017;104(2):170-182
  • Ritter K, Lange C, Weygandt M, Mäurer A, Roberts A, Estrella M, Suppa P, Spies L, Prasad V, Steffen I, Apostolova I, Bittner D, Gövercin M, Brenner W, Mende C, Peters O, Seybold J, Fiebach JB, Steinhagen-Thiessen E, Hampel H, Haynes JD, Buchert R. Combination of Structural MRI and FDG-PET of the Brain Improves Diagnostic Accuracy in Newly Manifested Cognitive Impairment in Geriatric patients. J Alzheimers Dis. 2016 Aug 26. [Epub ahead of print]
  • Fendler WP, Kratochwil C, Ahmadzadehfar H, Rahbar K, Baum RP, Schmidt M, Pfestroff A, Lützen U, Prasad V, Heinzel A, Heuschkel M, Ruf J, Bartenstein P, Krause BJ. [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Nuklearmedizin. 2016 Jun 28;55(3):123-8.
  • Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med. 2017 Jan;58(1):85-90. doi: 10.2967/jnumed.116.183194.
  • Janssen JC, Meißner S, Woythal N, Prasad V, Brenner W, Diederichs G, Hamm B, Makowski MR. Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT. Eur Radiol. 2017 Aug 4. doi: 10.1007/s00330-017-4994-6.
  • Janssen JC, Woythal N, Meißner S, Prasad V, Brenner W, Diederichs G, Hamm B, Makowski MR. . [68Ga]PSMA-HBED-CC Uptake in Osteolytic, Osteoblastic, and Bone Marrow Metastases of Prostate Cancer Patients. Mol Imaging Biol. 2017 Jul 13. doi: 10.1007/s11307-017-1101-y.
  • Merola E, Pavel ME, Panzuto F, Capurso G, Cicchese N, Rinke A, Gress TM, Iannicelli E, Prosperi D, Pizzichini P, Prasad V, Kump P, Lipp R, Partelli S, Falconi M, Wiedenmann B, Delle Fave G. Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications. J Clin Endocrinol Metab. 2017 May 1;102(5):1486-1494. doi: 10.1210/jc.2016-3732.
  • Prasad V, Brenner W, Modlin IM. How smart is peptide receptor radionuclide therapy of neuroendocrine tumors especially in the salvage setting? The clinician's perspective. Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):202-4
  • Prasad V, Bodei L, Kidd M, Modlin IM. Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths. Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1825-30